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Abstract
Background: The multicellular tumor spheroid (MCTS) is an in vitro model associating malignant-cell
microenvironment and 3D organization as currently observed in avascular tumors.
Methods: In order to evaluate the relevance of this model for pre-clinical studies of drug combinations, we
analyzed the effect of gemcitabine alone and in combination with the CHIR-124 CHK1 inhibitor in a Capan-2
pancreatic cell MCTS model.
Results: Compared to monolayer cultures, Capan-2 MCTS exhibited resistance to gemcitabine cytotoxic effect. This
resistance was amplified in EGF-deprived quiescent spheroid suggesting that quiescent cells are playing a role in
gemcitabine multicellular resistance. After a prolonged incubation with gemcitabine, DNA damages and massive
apoptosis were observed throughout the spheroid while cell cycle arrest was restricted to the outer cell layer,
indicating that gemcitabine-induced apoptosis is directly correlated to DNA damages. The combination of
gemcitabine and CHIR-124 in this MCTS model, enhanced the sensitivity to the gemcitabine antiproliferative effect
in correlation with an increase in DNA damage and apoptosis.
Conclusions: These results demonstrate that our pancreatic MCTS model, suitable for both screening and imaging
analysis, is a valuable advanced tool for evaluating the spatio-temporal effect of drugs and drug combinations in a
chemoresistant and microenvironment-depending tumor model.
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Background
Pancreatic ductal adenocarcinoma (PDAC) is one of the
most lethal cancers with less than 5% of overall patient
survival after 5 years. Local and distant invasion, resis-
tance to chemotherapy and radiotherapy and lack of
early detection are responsible for this poor prognosis.
Gemcitabine (2’,2’-difluorodeoxycytidine, a pyrimidine
nucleoside analogue) chemotherapy, is the standard
treatment of the patients. The combination of gemcita-
bine with other chemo- or biotherapies has resulted in a
very limited prognostic improvement. Recently, a high
throughput RNAi screen identified the checkpoint
kinase 1 (CHK1) as a gene conferring resistance to gem-
citabine in pancreatic cancer cells [1]. CHK1 is a key
component of the cell cycle checkpoints that are acti-
vated by genomic and replicative stress (review in [2]).
This checkpoint activation is known to facilitate DNA
repair. Consequently, CHK1 may play an important role
in the resistance of tumor cells to genotoxic therapy,
raising the possibility that inhibitors of checkpoint
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of cancer. In the case of pancreatic cancer, in vitro and
in vivo studies have shown that CHK inhibitors enhance
the antitumor activity of gemcitabine [3-5].
The MultiCellular Tumor Spheroid (MCTS) model is
generally considered as a better model than two dimen-
s i o n a lc u l t u r et op r e d i c tt h ei nv i v or e s p o n s et od r u g
treatments [6-8] and it is now widely accepted that
MCTS reproduce more accurately the tumor microen-
vironment than monolayer cell cultures. While growing,
spheroids display a gradient of proliferating cells from
the outer cell layers with quiescent cells located more
centrally. When deprived of oxygen and glucose, central
cells die and a necrotic zone is formed. This cell hetero-
geneity is similar to that found in avascular micro-
regions of tumors [9]. It is well established that solid
tumor environment induces the level of drug resistance
to many chemotherapeutic agents. This phenomenon,
called multicellular resistance [10], emerges as soon as
cancer cells have established contacts with surrounding
cells or extracellular matrix, i.e. its microenvironment.
In MCTS, cancer cells can acquire this multicellular
resistance by interacting efficiently in 3 dimensions with
their environment [10-12].
In order to contribute to the discovery of new anti
pancreatic cancer agents or new potent combinations
with gemcitabine, we describe here the development
and the validation of a new spheroid model mimicking
the structure and chemo resistance of pancreatic solid
tumors compared to conventional 2D cell culture mod-
els. We also present the spatio-temporal parameters of
the biological response of gemcitabine alone or com-
bined with a CHK1 inhibitor, CHIR-124.
Materials and methods
Reagents
Gemcitabine was purchased from Sigma. CHIR-124 was
a generous gift of Dr Alain Pierré (Institute de
Recherche Servier).
Cell culture
Capan-2 pancreatic cancer cells were cultured in
DMEM/F12 (Invitrogen, France) containing 10% FCS
with 2 mmol/l glutamine and penicillin/streptomycin in
a humidified atmosphere of 5% CO2 at 37°C. Capan-2
cells were transduced with a lentiviral vectors coding for
fused green -emitting fluorescent proteins to Geminin
[13].
Spheroid generation
Spheroids were prepared according to [14]. A Capan-2
cell suspension containing 10
4 cells/ml of DMEM/F12
supplemented with EGF (20 ng/ml) (Invitrogen) and
B27 (Invitrogen) was prepared. 100 μl of this cell
suspension were plated on each well of poly-HEMA-
coated 96-well plates. The plates were centrifugated at
200 g during 6 min and then incubated in a humidified
atmosphere of 5% CO2 at 37°C. By using this technique
we obtained single spheroids in each well, the variation
of size between spheroids is less than 10%. In order to
generate quiescent spheroids, after a first 4 days growth
phase in defined medium (DMEM/F12 supplemented
with EGF and B27), spheroids were washed twice with
media containing 10% FCS, and then incubated with
this media during 1-6 days.
Spheroid viability quantification
Spheroid viability was quantified by ATP monitoring
with the Perkin Elmer ATPlite™ assay system. This sys-
tem is based on the production of light caused by the
reaction of ATP, a cell viability marker present in cell
lysate, with added luciferase and D-luciferin. We
adapted ATPlite assay procedure for spheroid applica-
tion, especially concerning spheroid dissociation and cell
lysis. Then 100 μl of mammalian cell lysis solution
(ATPlite kit) were added to each well containing one
spheroid in 100 μl of culture medium. The plate was
shaken for 20 min. In order to read luminescent signal,
75 μl of the cell lysate was transferred to a black 96-well
plate. Then 37 μl of DMEM/F12 medium containing
10% FCS and 37 μl of ATPlite kit substrate solution
were added. After 15 min of shaking, the luminescence
signal was read on an Envision
® plate reader (Perkin
Elmer).
Immunofluorescence on frozen sections
Capan-2 spheroids were rinsed with PBS and fixed in
4% neutral-buffered formalin (Sigma) for 2 h. After fixa-
tion, spheroids were processed for 5 μm frozen sections.
Sections were incubated overnight at 4°C with antibo-
dies directed against cleaved form of PARP (rabbit
monoclonal, Epitomics, 1/1000), or gH2AX phosphory-
lated (mouse monoclonal, Upstate, 1/200) and Ki67
(rabbit polyclonal, Santa Cruz, 1/200). After washing in
PBS/Triton 0.1% v/v, the secondary antibody was
applied (Alexa 488-anti-mouse or Alexa 594-anti-rabbit,
Molecular Probes, 1/800, for 1 h at room temperature).
To determine cell cycle repartition, sections of Capan-2
spheroids expressing the green FUCCI probe were
directly analyzed by fluorescence imaging. The observa-
tions were based on the examination of 3 sections from
at least 5 spheroids. Each experiment has been repeated
a minimum of 3 times.
Cytotoxicity assays
Spheroids were generated using 1000 cells in 100 μlp e r
well as indicated in spheroid generation section. After 4
days of culture, chemotherapeutic agents or
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was evaluated by ATP quantification after 72 h com-
pound treatment. Tests were performed in triplicate and
the data presented are from at least three separate
experiments. ATP content percentage was calculated
with regard to non-treated spheroid and showed cell
growth inhibition and/or toxicity. The 50% effective
concentration (EC50) of a compound is the concentra-
tion which provokes 50% of the maximal effect (ATP
production decrease) of this drug. Curve fittings were
performed with GraphPad (San Diego, CA) Prism ver-
sion 4.0 software using the sigmoidal dose-response to
determine EC50 values.
Results
Generation of Capan-2 spheroids in microplate
In order to obtain a model of pancreatic multicellular
spheroid, we tested several pancreatic cancer cell lines
including BxPC3, MiaPaCa, Panc-1, AsPC-1, Capan-2. A
pancreatic cancer spheroid model was obtained only
with Capan-2 cell line. Seeding of 10
3 Capan-2 pancrea-
tic cancer cells in DMEM/F2 medium supplemented
with 10% serum allowed cell association and stabiliza-
tion in spherical structure after centrifugation. However,
whereas this medium allowed Capan-2 cell proliferation
in monolayer culture, it was not able to sustain Capan-2
cell growth in spheroid in 96-well plates (Figure 1a).
Consequently, different growth media composition were
evaluated and we found that defined DMEM/F12 med-
ium supplemented with EGF and B27 induced Capan-2
spheroid growth up to 16-fold between day 1 and day
10. Determination of cell viability by measurement of
cell ATP content (Figure 1b) confirmed that Capan-2
spheroids grown faster in the defined medium. Intra-
and inter-assay precision of spheroid volume and ATP
measurement was found to be suitable to ensure robust
pharmacological studies (variation of size and ATP were
less than 10%) (data not shown). To confirm the depen-
dence on EGF, Capan-2 spheroids were cultured in
defined medium supplemented with EGF. Four days
later, EGF was washed out and Capan-2 spheroids were
maintained in 10% serum. In this condition, we
observed that Capan-2 spheroid growth was inhibited
(Figure 1c).
The spheroid internal structure depends on a nutrient
and oxygen gradient which controls a decreasing gradi-
ent of cell proliferation from the periphery to the center
of spheroid. A central necrotic area is generally observed
in spheroids larger than 500 μm due to critical O2 con-
centration in the central zo n e[ 9 ] .W ed e t e r m i n e dt h e
repartition of proliferative and apoptotic cells in Capan-
2 spheroids of various sizes cultured in defined medium
supplemented with EGF and B27 (Figure 2). Formalin-
fixed tissue-teck-embedded Capan-2 spheroid sections
were immuno-stained for the proliferation and apoptotic
markers Ki-67 and cleaved PARP respectively. We
found that proliferative and non proliferative cells were
distributed throughout the 400 μms i z eC a p a n - 2s p h e r -
oid and a gradient of proliferation appears on spheroid
measuring 600 μm and more in diameter. While apopto-
sis was not detected in 400 μm spheroids, apoptotic
cells were observed in the center of the spheroid of lar-
ger diameters (Figure 2). Consequently, this model
allows the investigation of drug response taking into
account cell heterogeneity.
Resistance to gemcitabine treatment of the Capan-2
spheroid model
Considering increase in spheroid size, change in prolif-
eration gradient and the occurrence of a necrotic core,
we applied cytotoxic treatment (3 days) between days 4
and 7, thus avoiding overlapping effects. Indeed, we did
not observe significant difference in gemcitabine EC50
between 4, 5, 6 and 7 days spheroids (diameter ranging
from 400 to 600 μm) (data not shown). As a conse-
quence we cultured spheroids for four days before treat-
ment as this protocol is compatible with automated
HTS application. We first compared the effect of gemci-
tabine on Capan-2 cells growing as monolayer and as
spheroid. Figure 3 shows the effect of different gemcita-
bine concentrations on spheroid culture compared to
the monolayer culture. We observed that a 3 day treat-
ment with gemcitabine exerted a similar efficiency
(100% ATP decrease) but gemcitabine potency was
found to be much higher in monolayer culture (EC50 =
0.66 10
-7 M) compared to spheroids (EC50 = 4.2 10
-7
M) indicating that gemcitabine effect could be corre-
lated to multicellular growth condition.
To evaluate if this resistance is linked to the presence
of quiescent cells in the Capan-2 spheroid, we tested the
response to gemcitabine treatment of quiescent spher-
oids. Capan-2 spheroid need for EGF was used to
induce a quiescent state. As already shown in Figure 1c,
when Capan-2 spheroids were cultured in absence of
EGF in 10% serum, an inhibition of growth was
observed. In this condition the potency of gemcitabine
was 13-fold lower in quiescent Capan-2 spheroid than
in proliferative Capan-2 spheroid (Figure 3). Thus this
Capan-2 spheroid model mimics multicellular resistance
to gemcitabine.
Gemcitabine cytotoxicity in capan-2 spheroid is
associated with induction of DNA damage, cell cycle
perturbation and apoptosis
The gemcitabine cytotoxic effect is mediated by induc-
tion of DNA damage [15]. We used the spheroid model
to determine how gemcitabine-induced DNA damage
occurs in function of cell position within the spheroid.
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Figure 1 Growth of Capan-2 spheroids. The Capan-2 spheroids were grown in the presence of 10% serum (gray squares) or defined medium
added with EGF and B27 (black triangles) without any medium change (a and b). (a) Spheroid size. The diameter of each spheroid was
measured by microscopic observation with an ocular micrometer and sphere volume was calculated. (b) Cell viability. Spheroid viability was
quantified by ATP monitoring with the luminescent ATPlite assay. (c) Induction of a quiescent state on Capan-2 spheroid. Capan-2 spheroid
culture was initiated in presence of 10% serum and EGF and four days after culture initiation, EGF was (gray squares) or not (black triangles)
removed from the culture medium. Capan-2 spheroid viability was followed during a 6 days additional period with the luminescent ATPlite
assay. Each point is the mean ± SD of 6 spheroids.
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Page 4 of 11The Histone H2AX phosphorylation at Ser139 (g-
H2AX) was used as a marker of DNA damage. Immu-
nodetection of this phosphorylated form g-H2AX on
frozen sections of gemcitabine-treated Capan-2 spher-
oids (used at their EC50 value, 4.10
-7 M) showed that
DNA damage was restricted to the outer cell layer until
48 h after gemcitabine addition (Figure 4).
In order to monitor gemcitabine-induced cell cycle
intra-S and G2/M checkpoints response in a 3-D
context we used Capan-2 cells expressing FUCCI repor-
ter corresponding to the fluorescent protein geminin-
mAG (green) which accumulates in cell nuclei in S-,
G2- and M-phase [13]. In control spheroids the FUCCI-
green reporter was expressed in cells located throughout
the spheroid however the proportion of FUCCI-green
cells was higher in cells located in the outer cell layer
(Figure 4). In agreement with the fact that a S-phase
checkpoint is activated in response to gemcitabine [16],
KI67
400 μm 600  μm 800  μm 
Cleaved PARP
Figure 2 Distribution of proliferative and apoptotic cells in Capan-2 spheroids of different sizes. Ki-67 and cleaved form of PARP were
analyzed by immunodetection on 5 μm frozen sections in Capan-2 spheroids of different size. 400, 600 and 800 μm correspond respectively to
spheroid at days 4, 7, and 12 after culture initiation in defined medium supplemented with EGF and B27. The scale bar corresponds to 100 μm.
Results shown are representative of the examination of 3 sections from 5 spheroids. Each experiment has been repeated 3 times.
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Figure 3 Gemcitabine effect on cell viability after 72 h treatment on Capan-2 cells cultured as monolayer (open circle), spheroid in
defined medium supplemented with EGF and B27 (black triangles), or as quiescent Capan-2 spheroid (gray squares). Each point is the
mean ± SD of 3 replicates. Dose-response experiments were fitted with GraphPad Prism software.
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Page 5 of 11a 16 h treatment of Capan-2 spheroid with gemcitabine
resulted in a regionalization of the FUCCI green expres-
sing cells that located only in the outer cell layers. This
accumulation of cells in the S/G2/M phases of the cell
cycle was maintained 48 h after gemcitabine addition.
The therapeutic potential of gemcitabine results from
its ability to induce apoptosis in tumor cells. Gemcita-
bine-induced apoptosis was examined using immunode-
tection of cleaved form of PARP on frozen sections. We
found that, whereas apoptotic cells were not detected 16
h after addition of gemcitabine, a massive apoptosis
occurred throughout the spheroid after 48 h of treat-
ment (Figure 4).
Gemcitabine and CHIR-124 induced a synergistic
cytotoxic effect on capan-2 spheroid
Inhibitors of CHK1 have previously been shown to
enhance gemcitabine cytotoxic effect against pancreatic
cancer cells [3-5]. CHIR-124 is a potent inhibitor of
CHK1 activity [17]. CHIR-124 induced a decrease in
Capan-2 spheroid viability (EC50 = 6.7 10
-8 M; 100%
efficiency) (data not shown). We then determined the
impact of CHIR-124 on the sensibility of Capan-2
spheroid to gemcitabine. For combination experiments
we selected doses of CHIR-124 and gemcitabine below
their respective EC50. For several CHIR-124/Gemcita-
bine combinations, we observed a synergistic effect of
the two compounds corresponding to higher inhibition
potency than the addition of the two compounds tested
separately. For example, a co-treatment of Gemcitabine
and CHIR-124 at their EC20 resulted in a 79% ATP
decrease. Thus, at a sub-toxic concentration, CHIR-124
potentiated the cytotoxic effect of a low dose of gemci-
tabine (Figure 5).
CHIR-124 modulates the spatial response of capan-2
spheroid to gemcitabine
We tested whether the CHIR-124 potentiation of gemci-
tabine cytotoxic effect on Capan-2 spheroid correlates
with an increase in gemcitabine-induced DNA damage.
As shown in Figure 6 (after a 16 h treatment), a low
gemcitabine concentration had minimal effect on the
induction of DNA damage (gH2AX staining), apoptosis
(cleaved PARP) and accumulation of cells in S/G2/M
Control   16h   48h  
H2AXp
Green FUCCI 
probe 
Gemcitabine 4.10-7M
Cleaved 
PARP 
Figure 4 Spatio-temporal response of Capan-2 spheroid to gemcitabine. Analysis of gemcitabine response was done on 5 μmf r o z e n
sections of Capan-2 spheroids treated 16 h and 48 h with 4.10
-7 M gemcitabine. DNA damage was revealed by immunodetection of
phosphorylated of gH2AX, S phase checkpoint was monitored on Capan-2 spheroid expressing the geminin-mAG FUCCi green probe and
apoptosis was analyzed by immunodetection of cleaved form of PARP. Images were collected using a X10 objective. The scale bar corresponds
to 100 μm. Results shown are representative of the examination of 3 sections from 5 spheroids. Each experiment has been repeated 3 times.
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Page 6 of 11phases (FUCCI reporter) in the outer cell layer. CHIR-
124 at a low dose showed a very weak effect on cell
accumulation in the S/G2/M phase, apoptosis and DNA
damage. When CHIR-124 was combined with gemcita-
bine at these same doses, the effect on DNA damage
and apoptosis was significantly improved mainly in the
outer layer of the MCTS. All these measurements were
performed in several independent experiments as shown
for apoptosis image analysis (Additional file 1: Figure
S1). From these images, induced apoptosis was quanti-
fied by counting PARP-C positive cells per spheroid sec-
tion and showed a clear synergic effect (Additional file
2: Figure S2).
It has been reported that CHK inhibitors abrogate the
gemcitabine induced S phase checkpoint [3-5]. However,
in our combination experiments, the gemcitabine-
induced accumulation of cells in S/G2/M phases is too
low to observe a clear reversion of this effect in pre-
sence of CHIR-124 (Figure 6). These results indicated
that the potentiation of spheroid proliferation inhibition
of gemcitabine by CHIR-124 was associated with a cell
cycle checkpoint abrogation leading to the induction of
DNA damage and apoptosis.
Discussion
Standard chemotherapeutic drugs have limited effect in
large-scale clinical trials for pancreatic cancer. Because
of the very poor prognosis of this type of cancer, novel
approaches are therefore urgently needed. Most in vitro
screening approaches are based on monolayer culture of
pancreatic cancer cells but it is well established that
tumor microenvironment plays an important role in
response to chemotherapy. It is therefore of major
importance that more predictive pharmacological mod-
els be developed for the assessment of new therapeutic
strategies.
Multicellular Tumor Spheroids are of particular
interest as they offer a level of intermediate complexity
that recapitulate the three-dimensional organization of
a tumor and integrate the notion of microenvironment.
The production of 500-600 μml a r g es p h e r o i d sf r o m
various epithelial cancer cell lines has already been
shown for colon, breast, prostate and kidney but not
pancreas with the liquid overlay technology [18].
Spheroids from several pancreatic ductal adenocarci-
noma (PDAC) cell lines were obtained on micro-pat-
terned culture plates but no pharmacological analysis
were presented with these models [19]. Recently,
PDAC cell lines grown in 3D collagen microenviron-
ment were shown to proliferate in the presence of
gemcitabine whereas they stopped growing when culti-
vated on tissue culture plastic indicating that 3D cell
organisations could have an impact on pancreatic can-
cer cell drug sensitivity [20]. Then, the development of
new MCTS models represents an interesting way to
improve the discovery of new treatment. By using the
in vivo validated gemcitabine and CHIR124 molecules
[3], we show here that our Capan-2 MCTS model for
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Figure 5 Gemcitabine and CHIR-124 produce a synergistic cytotoxic effect on Capan-2 spheroid. Spheroids were treated for 72 h after 4
day initial culture with gemcitabine, CHIR-124 or a combination of the 2 compounds at concentration corresponding to their respective EC20
values. Spheroid viability was quantified at day 7 by ATP monitoring with the luminescent ATPlite assay. ATP content percentage was calculated
with regard to non-treated spheroid and showed cell growth inhibition and/or toxicity.
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Page 7 of 11pancreatic cancer could detect effective drug
combinations.
In this study we developed an “automation friendly”
spheroid model of Capan-2 pancreatic cancer cell spher-
oids in 96 well-plates. We chose ATP quantification to
measure the effect of chemical compounds on cell viabi-
lity and proliferation. We showed that epidermal growth
factor (EGF) was necessary to maintain Capan-2 cell
proliferation in a 3-D context, whereas it was not the
case in monolayer. It is well known that EGF plays an
important role in pancreatic cancer progression and
EGF and its ligand over-expression have been frequently
observed in pancreatic cancer [21,22]. A recent study
reporting the effects of EGF ligands in different culture
conditions of ovarian cancer cells clearly showed that in
contrast to monolayer culture, spheroids facilitated
growth stimulatory activity of EGF ligands [23]. This
EGF dependent-proliferation of spheroids emphasized
the relevance of this model by comparison with cell
monolayer and with tumor context. Moreover, the
EGFR systems and associated signaling pathway could
be promising targets for pancreatic cancer treatment
[24]. Consequently Capan-2 cell spheroid appears to be
a relevant model to screen for EGF signaling targeting
compounds.
A proliferation gradient was observed for spheroids
around 600 μm diameter: proliferative cells were located
in the outer layer whereas quiescent cells were located
more centrally. It has been previously shown that when
the central cells become deprived of oxygen and glucose,
cell death and necrosis occur [9]. According to this, we
found that apoptotic cells were detected in the spheroid
center after 7 days when the spheroid size reached 600
μm. This proportion greatly increased until day 12. The
characterization of the proliferation gradient in the
spheroid of different sizes clearly showed that there was
a window to test antitumoral compounds. This window
started when proliferation gradient was established (after
4 days) but before central necrosis appeared at onset of
treatment (before 7 days).
Most in vitro studies on the response of pancreatic
cancer cell to gemcitabine were based on monolayer cell
culture. A study reports that gemcitabine was less
potent when cancer cells were grown as multilayer
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Figure 6 Spatio-temporal response of Capan-2 spheroid to gemcitabine and Chk1 inhibitor. Analysis of gemcitabine response in presence
and absence of CHK1 inhibitor was done on 5 μm frozen sections of Capan-2 spheroids treated 16 h with 10
-7 M gemcitabine alone, 2 10
-8 M
CHIR-124 alone or the combination of gemcitabine and CHIR-124 at these same doses. DNA damage was revealed by immunodetection of
phosphorylated of gH2AX, S phase checkpoint was monitored on Capan-2 spheroid expressing the geminin-mAG Fucci green probe and
apoptosis was analyzed by immunodetection of cleaved form of PARP. Images were collected using a X10 objective. The scale bar corresponds
to 100 μm. Results shown are representative of the examination of 3 sections from 5 spheroids. Each experiment has been repeated 3 times.
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Page 8 of 11compared to monolayer cultures [25]. It is well estab-
lished that for many chemotherapeutic drugs a solid
tumor environment results in an increased level of drug
resistance, a phenomenon called the multicellular resis-
tance. Multicellular resistance emerges as soon as cancer
cells have established contacts with their microenviron-
ment, homologous cells, heterologous cells or extracellu-
lar matrix [10,26]. This contact dependent resistance
can be observed when cell are cultured as spheroid.
Spheroid culture of glioblastoma cells are less sensitive
to gemcitabine than monolayer cells [27]. Our results
show that pancreatic Capan-2 cells cultured as spheroids
are also less sensitive to gemcitabine than Capan-2
monolayer. This result agrees with a recent study show-
ing that a 3-D collagen microenvironment protects pan-
creatic cancer cells from gemcitabine-induced
proliferation arrest [20]. Spheroid permeability, presence
of quiescent and hypoxic cells could explain this resis-
tance [10]. Our observation that gemcitabine potency
was reduced in quiescent Capan-2 spheroid suggests
that pancreatic cancer cell proliferation status plays a
role in gemcitabine response.
DNA damage induced by gemcitabine results in acti-
vation of S cell cycle checkpoint and apoptosis [15]. In
addition to assess the global cytotoxicity of anticancer
agents, the spheroid model allows to image cell response
in function of their position within the spheroid [12,28].
H2AX phosphorylation, which has been demonstrated
as a pharmacodynamic indicator of gemcitabine-induced
stalled replication forks [15], was first used to image
gemcitabine response in Capan-2 spheroid. The estab-
lishment of gemcitabine-induced S phase checkpoint
was characterized by using Capan-2 cells expressing the
Fucci reporters corresponding to the fluorescent protein
geminin-mAG (green) that is expressed in S/G2/M
phases of the cell cycle. Our results show that 16 h after
gemcitabine addition only the cells located in the outer
cell layer are targeted by gemcitabine. Indeed, cells of
the outer cell layer are those with damaged DNA and
accumulated in the S/G2/M phases of the cell cycle.
This spatially confined DNA damage may result from
limited drug penetration or a low sensitivity of non-pro-
liferating cells in deeper spheroid layers. Our results do
not discriminate between these two hypotheses. One
limitation to gemcitabine efficacy is its poor penetration
in human tumors [22,29,30]. Using a multicellular layer
method to study drug penetration it has been shown
that the penetration of gemcitabine in multicellular cell
layer is independent of cell concentration but decrease
with the thickness of the layer [31]. 48 h after gemcita-
bine addition, cells arrested in the S phase remained
located in the outer cell layer whereas DNA damages
and apoptosis were detected throughout the spheroid
suggesting that DNA damage rather than cell cycle
arrest are correlated with apoptosis. This result agrees
with a previous study showing that in spheroids the per-
sistence of DNA damage determined by gH2AX staining
predicted clonogenic cell survival [32].
One field of spheroid interest is the study of drug
combination. Inhibition of CHK1 represents a targeted
approach to selectively enhance the cytotoxicity of
DNA-damaging agents in tumor cells. Whereas, p53-
deficient cells have been preferentially killed by the
combination of a DNA damaging agent, which arrest
the cell cycle in G2, followed by CHK1 inhibitor, p53-
proficient tumors could potentially be targeted by con-
current administration of an antimetabolite and a CHK1
inhibitor [33]. CHK1 inhibitors are able to potentiate
gemcitabine cytotoxicity in vitro and in vivo
[3,4,16,34,35]. In agreement with these results our data
show that gemcitabine and a CHK1 inhibitor (CHIR-
124) exert a synergistic cytotoxic effect on Capan-2
spheroid. This synergic cytotoxic effect was associated
with an increase in the ability of gemcitabine to trigger
DNA damage and apoptosis. Taken together these data
indicate that the spheroid model provide new informa-
tion concerning the role of cancer cell microenviron-
ment on the gemcitabine and CHK1 inhibitor pancreatic
cancer cell response.
Conclusions
In conclusion we have developed a 3-D model of pan-
creatic cancer cells growing as single spheroid with
homogenous size in 96 -well plates. The rationale for
using spheroid model in high throughput anticancer
drugs screening has been highlighted [8,35]. The Capan-
2 spheroid model may be useful in evaluating com-
pounds targeting the EGF signaling pathway. Further-
more our study underscores the predictive power of
three-dimensional culture to assess the pharmacological
activity of drug combination. While this model does not
really mimic in vivo situation, particularly for compound
delivery and stability, this model may partly reduce ani-
mal xenograft utilization. Pancreatic cancer spheroid
model could therefore serve as an intermediate deci-
sion-making step in the pre-clinical development of
drug combination for pancreatic cancer.
Additional material
Additional file 1: Figure S1. Induction of apoptosis upon exposure of
Capan-2 spheroid to Gemcitabine and CHIR-124. Analysis was performed
as described in Figure 6. Apoptosis was revealed by immunodetection of
cleaved form of PARP. Three sections from different spheroids are shown
here to illustrate the reproducibility of the observation. The scale bar
corresponds to 100 μm.
Additional file 2: Figure S2. Quantification of the induction of
apoptosis upon exposure of Capan-2 spheroid to Gemcitabine and CHIR-
124. Analysis was performed as described in Figure 6. Apoptosis was
Dufau et al. BMC Cancer 2012, 12:15
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Page 9 of 11revealed by immunodetection of cleaved form of PARP. Spheroid
sections were analyzed to quantify the number of cells with cleaved
PARP using the FIJI software (measure plugin). The data are expressed as
the percentage of spheroid sections displaying 0 to 10, 10 to 20, or more
than 20 PARP-C positive cells.
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